Skip to Content

Bystolic Approval History

Bystolic (nebivolol) is a once daily beta blocker approved for the treatment of hypertension.

Development History and FDA Approval Process for Bystolic

DateArticle
Dec 18, 2007Approval Bystolic, a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Dec  3, 2007FDA Issues Approvable Letter for Bystolic (nebivolol) for the Treatment of Hypertension
May  1, 2007Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Jun  1, 2005Mylan Laboratories Receives Approvable Letter For Its Next Generation Beta-Blocker Nebivolol
Feb 25, 2005FDA Extends PDUFA Action Date for Nebivolol Tablets to May 31, 2005
Jul  1, 2004Mylan's NDA for Nebivolol Accepted for FDA Review
May  5, 2004Mylan Submits New Drug Application for Nebivolol

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide